Loading
The trial that showed one look inside the lower bowel in your late fifties can prevent a bowel cancer for life, and that a single test is enough.
The UK Flexible Sigmoidoscopy Screening Trial offered 57,237 people a single flexible sigmoidoscopy between 55 and 64 and compared them with 113,195 who were not contacted. Seven in ten attended. After a median 11.2 years, colorectal cancer incidence in the invited group was 23 percent lower (hazard ratio 0.77, 0.70 to 0.84) and mortality 31 percent lower (0.69, 0.59 to 0.82); among those who actually attended, incidence fell 33 percent and mortality 43 percent, and incidence of distal cancer halved. The 17-year follow-up published in 2017 showed the benefit persisted. The result created Bowel Scope Screening in England, which was later withdrawn in favour of extending the faecal immunochemical test programme down to age 50; NHS England confirmed in January 2021 that bowel scope is no longer offered.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer and the tags uk, screening, colorectal.
Shares Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer and the tags uk, colorectal.
Shares Colonoscopy, Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer and the tag colorectal.
Shares Colorectal cancer and the tags uk, colorectal.
Shares Colonoscopy, Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood), Colorectal cancer and the tag colorectal.
Shares Colonoscopy, Colorectal cancer and the tag colorectal.
Shares Colorectal cancer and the tags uk, colorectal.
Shares Colorectal cancer and the tags uk, colorectal.